SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
-4.4%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(-0.41%)
Cap. Flow
+$24.4M
Cap. Flow
% of AUM
2.16%
Top 10 Holdings %
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
31
Reduced
26
Closed
23
Top Buys
| 1 |
Terns Pharmaceuticals
TERN
|
$33.7M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$32.4M |
| 3 |
Praxis Precision Medicines
PRAX
|
$20.5M |
| 4 |
Nurix Therapeutics
NRIX
|
$19.6M |
| 5 |
Enliven Therapeutics
ELVN
|
$18M |
Top Sells
| 1 |
Rigel Pharmaceuticals
RIGL
|
$67.4M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$47.1M |
| 3 |
United Therapeutics
UTHR
|
$37.7M |
| 4 |
GeneDx Holdings
WGS
|
$18.2M |
| 5 |
HCA Healthcare
HCA
|
$17.2M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Consumer Staples | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Janux Therapeutics
JANX
$1.37B
| $2.32M | 0.21% | 55,500 -102,300 | -65% | -$4.29M |
|
77
4D Molecular Therapeutics
FDMT
$288M
| $2.28M | 0.2% | 108,598 -88,500 | -45% | -$1.86M |
|
|
78
GeneDx Holdings
WGS
$3.72B
| $2.27M | 0.2% | 87,000 -696,376 | -89% | -$18.2M |
|
79
CervoMed
CRVO
$83.7M
| $2.17M | 0.19% | 126,614 | – | – |
|
80
Avita Medical
RCEL
$117M
| $2.11M | 0.19% | 267,000 +192,000 | +256% | +$1.52M |
|
81
NovoCure
NVCR
$1.38B
| $1.87M | 0.16% | 108,900 -586,859 | -84% | -$10.1M |
|
82
Inhibrx
INBX
$408M
| $1.25M | 0.11% | +88,470 | New | +$1.25M |
|
83
Oric Pharmaceuticals
ORIC
$994M
| $1.15M | 0.1% | 163,000 -258,000 | -61% | -$1.82M |
|
84
Adverum Biotechnologies
ADVM
$64.6M
| $1.01M | 0.09% | +147,246 | New | +$1.01M |
|
85
Establishment Labs
ESTA
$1.2B
| $682K | 0.06% | +15,000 | New | +$682K |
|
86
Orthofix Medical
OFIX
$592M
| $676K | 0.06% | +51,000 | New | +$676K |
|
87
MiMedx Group
MDXG
$1.05B
| $574K | 0.05% | +82,884 | New | +$574K |
|
|
WHWK
88
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $487K | 0.04% | +333,227 | New | +$487K |
|
|
BCYC
89
Bicycle Therapeutics
BCYC
$511M
| $476K | 0.04% | 23,500 -129,500 | -85% | -$2.62M |
|
90
Natera
NTRA
$23.1B
| $390K | 0.03% | 3,600 -83,400 | -96% | -$9.03M |
|
91
IO Biotech
IOBT
$104M
| $225K | 0.02% | +192,670 | New | +$225K |
|
92
Xeris Biopharma Holdings
XERS
$1.26B
| $140K | 0.01% | 62,083 | – | – |
|
93
Annexon
ANNX
$226M
| – | – | -292,400 | Closed | -$2.1M |
|
94
Apogee Therapeutics
APGE
$2.17B
| – | – | -20,000 | Closed | -$1.33M |
|
95
Arcutis Biotherapeutics
ARQT
$1.86B
| – | – | -225,000 | Closed | -$2.23M |
|
96
Biogen
BIIB
$19.4B
| – | – | -72,800 | Closed | -$15.7M |
|
|
CMPS
97
Compass Pathways
CMPS
$424M
| – | – | -565,550 | Closed | -$4.71M |
|
98
Denali Therapeutics
DNLI
$2.23B
| – | – | -47,000 | Closed | -$964K |
|
99
Dianthus Therapeutics
DNTH
$759M
| – | – | -100,000 | Closed | -$3M |
|
100
Amicus Therapeutics
FOLD
$2.34B
| – | – | -57,966 | Closed | -$683K |
|